Anti-Inflammatory Mechanisms in Psychiatric Pharmacotherapy

Emerging evidence implicates chronic inflammation as a key contributor to the onset and progression of major psychiatric conditions. Beyond their classical actions on monoamine or glutamate systems, many psychotropic agents possess intrinsic anti-inflammatory properties that may underlie part of their therapeutic efficacy. These mechanisms include suppression of pro-inflammatory cytokine production both peripherally and centrally, inhibition of microglial activation and inflammasome assembly, modulation of intracellular signalling cascades such as mitogen-activated protein kinases and nuclear factor-κB, and promotion of neuroprotective mediators including neurotrophic factors and neurosteroids. By shifting the balance from a pro-inflammatory to an anti-inflammatory state, antidepressants, antipsychotics and mood-stabilisers can attenuate synaptic impairment, protect against neuronal apoptosis and restore homeostatic cross-talk between the immune and nervous systems. This immunomodulatory dimension of psychiatric pharmacotherapy offers novel opportunities for personalised interventions, drug repurposing and adjunctive strategies in disorders where inflammation plays a central role.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Anti-Inflammatory Mechanisms in Psychiatric Pharmacotherapy publication trend

The graph below shows the total number of articles in anti-inflammatory mechanisms in psychiatric pharmacotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

Sigma-1 receptor: a chaperone protein located at endoplasmic reticulum–mitochondrial junctions that regulates cellular stress responses and modulates neuroinflammatory signalling.

Neurosteroids: steroidal molecules synthesised in the brain that influence synaptic transmission, neuronal excitability and inflammatory processes.

Microglial activation: phenotypic shift of brain-resident immune cells towards a pro-inflammatory (M1) or anti-inflammatory (M2) state in response to injury or pathogens.

Lipopolysaccharide (LPS): a bacterial endotoxin commonly used in experimental models to induce robust inflammatory responses.

Long-term potentiation (LTP): a sustained increase in synaptic strength that serves as an in vitro correlate of learning and memory.

Pro-inflammatory cytokines: small signalling proteins such as interleukin-1β and tumour necrosis factor-α that mediate and amplify inflammatory responses.

References

1. SSRIs differentially modulate the effects of pro-inflammatory stimulation on hippocampal plasticity and memory via sigma 1 receptors and neurosteroids. Translational Psychiatry (2023).
2. Modulation of microglial activation by antidepressants. Journal of Psychopharmacology (2022).
3. The neurodegenerative hypothesis of depression and the influence of antidepressant medications. European Journal of Pharmacology (2024).